Posts tagged "Pipeline"

Oil Across Arabia: Transarabian Pipeline Construction pt1-3 1947 Bechtel 15min

video for embedding at news.quickfound.net part 2: www.youtube.com part 3: www.youtube.com This public domain video from the National Archives has been re-encoded to correct the aspect ratio. Mild noise reduction was also applied. From “The Building of Tapline” almashriq.hiof.no In 1950, the world’s largest oil pipeline system was completed. Oil fields in Saudi Arabia were linked with the Mediterranean Sea at Sidon, Lebanon, over a thousand miles away. The pipeline greatly reduced the number of tankers required to transport oil around the Arabian Peninsula through the Suez Canal to the Mediterranean, a 20-day, 7000 mile trip. The building of the great pipeline is a story of accomplishment by Americans and Middle Easterners working together towards a common goal. It took the courage, perseverence and skills of 16000 men, most of them nationals of the lands through which the line was passing, to overcome the heat, desert, sand storms, loneliness and other obstacles that beset the pipeliners during the construction period. At the Mediterranean, the oil is loaded on tankers and transported to the world markets. Though the trans-Arabian pipeline is 1068 miles long, only the 753 mile section from the Sidon Terminal to the Qaisumah pump station is rightly called the TRANS-ARABIAN PIPELINE or TAPLINE. The remaining 315 miles is part of the Arabian American Oil Company’s gathering system in eastern Saudi Arabia. This part of the line gathers the oil before its long journey to the …

Technorati Tags: 15min, 1947, Across, arabia, Bechtel, construction, Pipeline, pt13, Transarabian

Oil Across Arabia: Transarabian Pipeline Construction pt3-3 1947 Bechtel 14min

video for embedding at news.quickfound.net part 1: www.youtube.com part 2: www.youtube.com This public domain video from the National Archives has been re-encoded to correct the aspect ratio. Mild noise reduction was also applied. From “The Building of Tapline” almashriq.hiof.no In 1950, the world’s largest oil pipeline system was completed. Oil fields in Saudi Arabia were linked with the Mediterranean Sea at Sidon, Lebanon, over a thousand miles away. The pipeline greatly reduced the number of tankers required to transport oil around the Arabian Peninsula through the Suez Canal to the Mediterranean, a 20-day, 7000 mile trip. The building of the great pipeline is a story of accomplishment by Americans and Middle Easterners working together towards a common goal. It took the courage, perseverence and skills of 16000 men, most of them nationals of the lands through which the line was passing, to overcome the heat, desert, sand storms, loneliness and other obstacles that beset the pipeliners during the construction period. At the Mediterranean, the oil is loaded on tankers and transported to the world markets. Though the trans-Arabian pipeline is 1068 miles long, only the 753 mile section from the Sidon Terminal to the Qaisumah pump station is rightly called the TRANS-ARABIAN PIPELINE or TAPLINE. The remaining 315 miles is part of the Arabian American Oil Company’s gathering system in eastern Saudi Arabia. This part of the line gathers the oil before its long journey to the …
Video Rating: 0 / 5

Technorati Tags: 14min, 1947, Across, arabia, Bechtel, construction, Pipeline, pt33, Transarabian

Lung Cancer Therapeutic Antibodies: Pipeline, Strategies and Clinical  

Lung Cancer Therapeutic Antibodies: Pipeline, Strategies and Clinical  

Article by Bharatbook

Bharatbook added a new report on ” Lung Cancer Therapeutic Antibodies: Pipeline, Strategies and Clinical ” which gives an overview, Demand, Supply Trends and industry analysis reports.This report provides a comprehensive review of 27 candidate that are being evaluated for the treatment of ; covering pipeline, disease-targeting strategies and clinical findings. These antibodies are directed at 17 potential targets.

Globally, is the most common cancer and in 2008 there were an estimated 1.6 million new cases and 1.4 million deaths (almost 20% of all cancer deaths) caused by this disease. Five-year survival rates are also low (15-20%) compared to other common cancers. In the US, studies have shown that -care costs (in 2006) were the third highest of all cancers, while indirect costs (2005) were higher than for any other cancer.

Patient needs and the high burden of on society drive the development of new therapies. While improvements have been seen in diagnosis and treatments (surgery, radiotherapy, chemotherapy and targeted drugs), new therapies that build on the capabilities of existing approaches, are urgently required

Today, developments continue to be made in drug treatments for ; in chemotherapy, new drug combinations, and targeted molecules. In particular, advances are being seen in the field of immunotherapy; in the development of new and therapeutic vaccines.

This Report

This report (see brochure) provides a comprehensive review of and reviews R&D and clinical developments in the treatment of as the primary indication, as well as studies that are evaluating cancer alongside other cancers.

Today, more than 25 candidate therapeutic antibodies are in development or are being evaluated for the treatment of , most of which are already in clinical trials. This field is also showing substantial innovation and these molecules are being directed at 17 different targets. This report gives an overview of the status and clinical findings of these candidate vaccines, together with developmental and market-related perspectives in this field.

Key content:

• Late-stage (Phases 2/3, 3 and Approved, n = 4) pipeline and companies• Early-stage (Preclinical and Phases 1, 1/2 and 2, n= 23) pipeline and companies• Other (mainly antibody related, n=6) candidate therapies in the development pipeline for targeting , Phase 1, 1/2 and 2• Drug targets being targeted by from preclinical through to Phase 3, and Approved• Descriptions of clinical trials (patients and numbers, conditions, treatments, regimens, Phase 1-3) of being evaluated for the treatment of • Summaries of clinical status and clinical findings (safety, adverse events and multiple event-related clinical responses) reported following clinical trials (Phase 1-3) of being evaluated for the treatment of • Commercial partnerships and collaborations on pipeline therapeutic antibodies• Drug combination strategies in the evaluation of the targeting of • A comprehensive listing of salient details of clinical trials of being evaluated for the treatment of • Technical and market insights and perspectives in the development and clinical evaluation of the treatment of • Competitive and market-related information

Tables

• 1.1 Global incidence and mortality from lung cancer, 2008• 1.2 NSCLC survival rates, according to cancer stage• 1.3a Five-year relative cancer survival rates in the USA for white males• 1.3b Five-year relative cancer survival rates in the USA for white females• 1.4 US national expenditure on different cancers (2006)• 1.5 US lost productivity due to different cancer types in the US, 2005• 2.1 Approved/late-stage candidate the treatment of • 3.1 Early-stage being developed or evaluated for the treatment of lung cancer or for /other cancers• 4.1 Other (largely antibody-related) therapies being developed or evaluated for the treatment of lung cancer or other cancers• 5.1 Approved/late-stage being developed for the treatment of lung cancer• 5.2 Early-stage candidate being developed or evaluated for the treatment of lung cancer or for other cancers• 5.3 Other (primarily antibody-related) therapies in development or being evaluated for lung cancer or for other cancers• 5.4 Approved/candidate the treatment of for lung cancer/other cancers• 5.5 Other candidate therapies (primarily antibody-related) for the treatment of lung cancer or for other cancers• 5.6 NSCLC survival rates, according to cancer stage

Figures

• 3.1 Early-stage pipeline therapeutic antibodies for the treatment of lung cancer or other cancers• 5.4 Approved and pipeline being developed or evaluated for the treatment of lung cancer or for lung/other cancers• 5.6 Other (primarily antibody-related) early-stage candidate therapies in development or being evaluated for lung cancer/other cancers• 5.10 Organisations developing or evaluating lung cancer therapeutic antibodies• 5.12 Clinical trials of the treatment of lung cancer or lung cancer/other cancers, involving single or combination agents

For more information kindly visit : http://www.bharatbook.com/detail.asp?id=213744&rt=Lung-Cancer-Therapeutic-Antibodies-Pipeline-Strategies-and-Clinical.html

Or

Contact us at :

Bharat Book BureauTel: +91 22 27578668 / +91 22 27579438Fax: +91 22 27579131Email: info@bharatbook.comWebsite: http://www.bharatbook.com

About the Author

Bharat Book Bureau, the leading market research information aggregator provides company profiles, country reports, newsletters, and online databases for the past twenty four years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our market research reports help global companies to know different market before starting up business / expanding in different countries across the world.

Technorati Tags: antibodies, Cancer, Clinical  , Lung, Pipeline, Strategies, therapeutic

Lung Cancer Vaccines and Therapeutic Antibodies: Pipeline, Strategies and Clinical, 2011  

Lung Cancer Vaccines and Therapeutic Antibodies: Pipeline, Strategies and Clinical, 2011  

Article by Bharatbook

Bharatbook added a new report on ” Lung Cancer Vaccines and Therapeutic Antibodies: Pipeline, Strategies and Clinical, 2011 ” which gives an overview, Demand, Supply Trends and industry analysis reports.This report provides a comprehensive review of 27 candidate therapeutic antibodies and 42 candidate vaccines that are being evaluated for the treatment of covering pipeline, disease-targeting strategies and clinical findings. These antibodies are directed at 17 targets, while the vaccines are directed at 24 antigens or antigen combinations.

Globally, the most common cancer and in 2008 there were an estimated 1.6 million new cases and 1.4 million deaths (almost 20% of all cancer deaths) caused by this disease. Five-year survival rates are also low (15-20%) compared to other common cancers. In the US, studies have shown that lung cancer-care costs (in 2006) were the third highest of all cancers, while indirect costs (2005) were higher than for any other cancer.

Patient needs and the high burden of are driving the development of new therapies. While improvements have been seen in diagnosis and treatments (surgery, radiotherapy, chemotherapy and targeted drugs), new therapies that build on the capabilities of existing strategies, are urgently required. Today, advances continue to be made in drug treatments for chemotherapy, new drug combinations and targeted molecules. In particular, advances are being seen in the field of immunotherapy, in the development of new therapeutic antibodies and therapeutic vaccines.

This Report

This report provides a comprehensive review of lung cancer immunotherapy. With a focus on therapeutic vaccines and antibodies, it reviews R&D and clinical developments in the treatment of as the primary indication, as well as studies that are evaluating lung cancer alongside other cancers. It provides a comprehensive review of pipeline developments, therapeutic strategies and clinical findings, covering therapeutic vaccines and antibodies.

Today, around 70 immunotherapies are being developed or evaluated for the treatment of lung cancer. This report reviews developments on 27 candidate therapeutic antibodies and 42 candidate vaccines for treating most of which are in clinical development.

The immunotherapy pipeline is showing substantial innovation and many new strategies are being evaluated. Today’s pipeline of therapeutic antibodies are directed at 17 drug targets. On the vaccine front, 24 different antigen/multiple antigen targeting strategies are being investigated. For the purpose of this report, multiple antigen targeting vaccines have been treated as single targeting strategies.

More than 90% of the immunotherapy candidates in development or being evaluated for treating are identified in this report, are in clinical development. This report gives an overview of the status and clinical findings of these candidate therapies. It also gives developmental and market-related perspectives in this rapidly developing field.

Key content:

• Late-stage (Phases 2/3, 3 and Approved, n = 4) therapeutic antibodies and companies• Early-stage (Preclinical and Phases 1, 1/2 and 2, n= 23) therapeutic antibodies and companies• Late-stage (Phases 2/3, 3 and Approved, n = 5) vaccines and companies• Early-stage (Preclinical and Phases 1, 1/2 and 2, n= 37) vaccines and companies• Other (mainly antibody related, n=6) candidate therapies in the development pipeline for targeting hases 1, 1/2 and 2• Drug targets against which therapeutic antibodies are being directed, from preclinical through to Phase 3, and Approved• Antigen/antigen combinations being targeted by vaccines, from preclinical through to Phase 3, and Approved• Descriptions of clinical trials (patients and numbers, conditions, treatments, regimens, Phases 1-3) of therapeutic antibodies and vaccines being evaluated for the treatment of lung cancer• Summaries of the clinical status and clinical findings (safety, adverse events and multiple event-related clinical responses), following clinical trials (Phases 1-3) of therapeutic antibodies being evaluated for the treatment of lung cancer• Summaries of the clinical status and clinical findings (safety, adverse events and multiple event-related clinical responses), following clinical trials (Phases 1-3) of vaccines being evaluated for the treatment of lung cancer• Commercial partnerships and collaborations on pipeline therapeutic antibodies and vaccines• Drug combination strategies in the evaluation of therapeutic antibodies and vaccines for targeting• A comprehensive listing of salient details of clinical trials of therapeutic antibodies and vaccines being evaluated for the treatment of lung cancer• Technical and market insights and perspectives in the development and clinical evaluation of therapeutic antibodies and vaccines for the treatment of lung cancer• Competitive and market-related information

For more information kindly visit : http://www.bharatbook.com/detail.asp?id=213740&rt=Lung-Cancer-Vaccines-and-Therapeutic-Antibodies-Pipeline-Strategies-and-Clinical-2011.html

Or

Contact us at :

Bharat Book BureauTel: +91 22 27578668 / +91 22 27579438Fax: +91 22 27579131Email: info@bharatbook.comWebsite: http://www.bharatbook.com

About the Author

Bharat Book Bureau, the leading market research information aggregator provides company profiles, country reports, newsletters, and online databases for the past twenty four years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our market research reports help global companies to know different market before starting up business / expanding in different countries across the world.

Find More Survival Rate Lung Cancer Articles

Technorati Tags: 2011  , antibodies, Cancer, Clinical, Lung, Pipeline, Strategies, therapeutic, Vaccines

Lung Cancer Vaccines: Pipeline, Strategies and Clinical  

by Barry Gourmet and Raw

Lung Cancer Vaccines: Pipeline, Strategies and Clinical  

Article by Bharatbook

Bharatbook added a new report on ” Lung Cancer Vaccines: Pipeline, Strategies and Clinical ” which gives an overview, Demand, Supply Trends and industry analysis reports.This report provides a comprehensive review of 42 candidate vaccines that are being evaluated for the treatment of covering pipeline, disease-targeting strategies and clinical findings. These vaccines are directed at 24 antigens or antigen combinations.

Globally, the most common cancer and in 2008 there were an estimated 1.6 million new cases and 1.4 million deaths (almost 20% of all cancer deaths) caused by this disease. Five-year survival rates are also low (15-20%) compared to other common cancers. In the US, studies have shown that lung cancer-care costs (in 2006) were the third highest of all cancers, while indirect costs (2005) were higher than for any other cancer.

Patient needs and the high burden of drive the development of new therapies. While improvements have been seen in diagnosis and treatments (surgery, radiotherapy, chemotherapy and targeted drugs), new therapies that build on the capabilities of existing approaches, are urgently required. Today, developments continue to be made in drug treatments for in chemotherapy, new drug combinations and targeted molecules. In particular, advances are being seen in the field of immunotherapy; in the development of new therapeutic antibodies and therapeutic vaccines.

This Report

This report (see brochure) provides a comprehensive review of vaccines and reviews R&D and clinical developments in the treatment of as the primary indication, as well as studies that are evaluating alongside other cancers.

Today, more than 40 candidate vaccines are in development or being evaluated for the treatment of most of which are already in clinical trials. This field is also showing substantial innovation and 24 different antigen/multiple antigen targeting strategies are being investigated. For the purpose of this report, multiple antigen targeting approaches have been treated as single strategies. This report gives an overview of the status and clinical findings of these candidate vaccines, and gives developmental and market-related perspectives in this rapidly developing field.

Key content:

• Late-stage (Phases 2/3, 3 and Approved, n = 5) pipeline vaccines and companies• Early-stage (Preclinical and Phases 1, 1/2 and 2, n= 37) pipeline vaccines and companies• Other (mainly antibody related, n=6) candidate therapies in the development pipeline for targeting Phase 1, 1/2 and 2• Antigens/antigen combinations being targeted by vaccines from preclinical through to Phase 3 and Approved• Descriptions of clinical trials (patients and numbers, conditions, treatments, regimens, Phase 1-3) of therapeutic vaccines being evaluated for the treatment. • Summaries of clinical status and clinical findings (safety, adverse events and multiple event-related clinical responses) reported following clinical trials (Phase 1-3) of vaccines being evaluated for the treatment of lung cancer• Commercial partnerships and collaborations on pipeline therapeutic vaccines• Drug combination strategies in the evaluation of therapeutic vaccines for the targeting.• A comprehensive listing of salient details of clinical trials of therapeutic vaccines being evaluated for the treatment.• Technical and market insights and perspectives in the development and clinical evaluation of therapeutic vaccines for the treatment.• Competitive and market-related information

Tables

Global incidence and mortality from 2008NSCLC survival rates, according to cancer stage1.3a Five-year relative cancer survival rates in the USA for white males1.3b Five-year relative cancer survival rates in the USA for white femalesUS national expenditure on different cancers (2006)US lost productivity due to different cancer types in the US, 20052.1 Approved/late-stage vaccines for the treatment of lung cancer3.1 Early-stage vaccines being developed or evaluated for the treatment of lung cancer/other cancers4.1 Other (largely antibody-related) therapies being developed or evaluated for the treatment of other cancers5.1 Approved/late-stage candidate vaccines being developed for the treatment of lung cancer5.2 Early-stage candidate vaccines being developed or evaluated for lung/other cancersOther (primarily antibody-related) therapies in development or being evaluated for lung cancer/other cancersApproved/candidate vaccines for the treatment of for other cancersOther candidate therapies (primarily antibody-related) for the treatment of for other cancersNSCLC survival rates, according to cancer stage

Figures

3.1 Early-staged pipeline vaccines for the treatment of lung cancer or other cancers5.1 Early-stage pipeline vaccines in development or being evaluated for lung/other cancers5.2 Other (primarily antibody-related) early-stage candidate therapies in development or being evaluated for other cancers5.3 Organisations developing or evaluating lung cancer therapeutic vaccines5.4 Clinical trials of vaccines for the treatment of other cancers, involving single or combination agents

For more information kindly visit : http://www.bharatbook.com/detail.asp?id=213743&rt=Lung-Cancer-Vaccines-Pipeline-Strategies-and-Clinical.html

Or

Contact us at :

Bharat Book BureauTel: +91 22 27578668 / +91 22 27579438Fax: +91 22 27579131Email: info@bharatbook.comWebsite: http://www.bharatbook.com

About the Author

Bharat Book Bureau, the leading market research information aggregator provides company profiles, country reports, newsletters, and online databases for the past twenty four years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our market research reports help global companies to know different market before starting up business / expanding in different countries across the world.

Technorati Tags: Cancer, Clinical  , Lung, Pipeline, Strategies, Vaccines

Idiopathic Pulmonary Fibrosis – Pipeline Assessment and Market Forecasts to 2017  

by Pulmonary Pathology

Idiopathic Pulmonary Fibrosis – Pipeline Assessment and Market Forecasts to 2017  

Article by Aarkstore Enterprise

Aarkstore announce a new report “Idiopathic Pulmonary Fibrosis – Pipeline Assessment and Market Forecasts to 2017″ through its vast collection of market research report.

Summary

Pharmaceutical and healthcare report, “Idiopathic Pulmonary Fibrosis – Pipeline Assessment and Market Forecasts to 2017” is an essential source of information and analysis on the global idiopathic pulmonary fibrosis market. The report identifies the key trends shaping and driving the global idiopathic pulmonary fibrosis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global idiopathic pulmonary fibrosis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

The global Idiopathic Pulmonary Fibrosis (IPF) market was valued at m in 2009. It is expected to increase with a compound annual growth rate (CAGR) of 23% from m in 2009 to 2m by 2017. Earlier, the IPF market was underserved due to a lack of approved products. In October 2008, the Japanese manufacturer Shionogi received approval for Pirespa in Japan. It is under regulatory review for approval in the US and EU. The expected increase in sales is due to the expected approval of Pirespa in the US and the EU and also the expected launch of Tracleer and Letiaris. Growth in the IPF market is being driven by the sales of Pirespa, off-label drug use and the anticipated approval of Letiaris and Tracleer. Gilead’s Letiaris and Actelion’s Tracleer are the most anticipated molecules in the IPF market.

Scope

The report provides information on the key driver and challenges of the idiopathic pulmonary fibrosis market. Its scope includes:- Annualized global idiopathic pulmonary fibrosis market revenues data from 2001 to 2009, forecast forward for eight years to 2017.- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Key classes of mechanism of action include enzyme inhibitors, protein inhibitors, endothelin A antagonists, combination therapy, TNF alpha antagonists, platelet aggregation inhibitors, interferon alpha, interleukin inhibitors, immunosuppresants, growth hormone inhibitors, gene therapy, LPA1 receptor antagonists, tumor growth factor inhibitors and NK-1 antagonists.- Analysis of the current and future market competition in the global idiopathic pulmonary fibrosis market. Key market players covered are Gilead Sciences, Actelion Ltd., Amgen Inc., InterMune Inc. and Amarillo Biosciences.- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the future market associated with idiopathic pulmonary fibrosis therapeutics.

For more information, please visit:http://www.aarkstore.com/reports/Idiopathic-Pulmonary-Fibrosis-Pipeline-Assessment-and-Market-Forecasts-to-2017-65417.htmlOr email us at press@aarkstore.com or call +919272852585

About the Author

Aarkstore Enterprise specialize in providing online market business information on market research reports, books, magazines, conference booking at competitive prices, and strive to provide excellent and innovative service to our customers.

Technorati Tags: 2017  , Assessment, Fibrosis, Forecasts, idiopathic, lpa1 antagonist, market, Pipeline, pirespa sales revenue in japan, pulmonary

Head and Neck Cancer – Pipeline Assessment and Market Forecast to 2017 Aarkstore Enterprise  

by sniperslaststand

Head and Neck Cancer – Pipeline Assessment and Market Forecast to 2017 Aarkstore Enterprise  

Article by Twinkle

Aarkstore announce a new report “Head and Neck Cancer – Pipeline Assessment and Market Forecast to 2017″ through its vast collection of market research report.

Summary

The industry analysis specialist’s new report, “Head and Neck Cancer – Pipeline Assessment and Market Forecast to 2017” is an essential source of information and analysis on the global head and neck cancer market. The report identifies the key trends shaping and driving the global head and neck cancer market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global head and neck cancer sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:- Annualized global head and neck cancer market revenues data from 2001 to 2009, forecast forward for 8 years to 2017.- Geographic markets covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.- Analysis of the current and future market competition in the global head and neck cancer market.- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with head and neck cancer

Reasons to buy

The report will enhance your decision making capability. It will allow you to:- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.- Develop business strategies by understanding the trends shaping and driving the global head and neck cancer market.- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global head and neck cancer market in future.- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.- What’s the next big thing in the global head and neck cancer market landscape? – Identify, understand and capitalize.

For more information, please visit:http://www.aarkstore.com/reports/Head-and-Neck-Cancer-Pipeline-Assessment-and-Market-Forecast-to-2017-77347.htmlOr email us at press@aarkstore.com or call +919272852585

About the Author

Aarkstore Enterprise specialize in providing online market business information on market research reports, books, magazines, conference booking at competitive prices, and strive to provide excellent and innovative service to our customers.

Find More Head And Neck Cancer Articles

Technorati Tags: 2017, Aarkstore, Assessment, Cancer, Enterprise  , forecast, Head, market, Neck, Pipeline

Malignant Mesothelioma – Pipeline Review, Q1 2011

Malignant Mesothelioma – Pipeline Review, Q1 2011

Malignant Mesothelioma – Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, ‘Malignant Mesothelioma – Pipeline Review, Q1 2011′, provides an overview of the Malignant Mesothelioma therapeutic pipeline. This report provides information on the therapeutic development for Malignant Mesothelioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Malignant Mesotheli

List Price: $ 500.00

Price:

Technorati Tags: 2011, Malignant, Mesothelioma, Pipeline, review

Bristol-Myers touts its cancer medicine pipeline

Bristol-Myers touts its cancer medicine pipeline
The Associated Press The Associated Press CHICAGO Bristol-Myers Squibb Co. executives say they have six cancer drugs in testing against different cancers and could get important data on them and possibly a couple of approvals this year. Skin cancer drug Yervoy, approved in the U.S. in March for patients who’ve failed on another therapy, could get approved in Europe soon. It works by stimulating …
Read more on Washington Examiner

Safeways 11th Annual Prostate Cancer Fundraiser Kicks Off in Stores
Safeway Inc. (NYSE:SWY) launched its month-long Prostate Cancer Campaign, a fundraising and awareness …
Read more on Finanzen.net

Technorati Tags: BristolMyers, Cancer, Medicine, Pipeline, touts

Peritoneal Cancer – Pipeline Review, Q1 2011 Reviews

Peritoneal Cancer – Pipeline Review, Q1 2011

Peritoneal Cancer – Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, ‘Peritoneal Cancer – Pipeline Review, Q1 2011′, provides an overview of the Peritoneal Cancer therapeutic pipeline. This report provides information on the therapeutic development for Peritoneal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peritoneal Cancer. ‘Peritoneal Cancer -

List Price: $ 500.00

Price: $ 500.00

More Peritoneal Cancers Products

Technorati Tags: 2011, Cancer, Peritoneal, Pipeline, review, Reviews

Reportlinker Adds Testicular Cancer Therapeutics – Pipeline Assessment and Market Forecasts to 2017

Cancer Treatment

Image by PNNL – Pacific Northwest National Laboratory
To treat cancer, IsoRay, Inc. is developing an advanced form of radiation-emitting seeds that are implanted in confined tumors. The Richland startup company has received a variety of assistance from Pacific Northwest National Laboratory and other local and regional organizations.

For more information, visit www.pnl.gov/news/

Reportlinker Adds Testicular Cancer Therapeutics – Pipeline Assessment and Market Forecasts to 2017
NEW YORK , June 1, 2011 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue: Testicular Cancer Therapeutics – Pipeline Assessment and Market Forecasts to 2017 http://www.reportlinker.com/p0546796/Testicular-Cancer-Therapeutics—Pipeline-Assessment-and-Market-Forecasts-to-2017.html?utm_source=prnewswire&utm_medium …
Read more on PR Newswire via Yahoo! Finance

Cookies for Kids’ Cancer Awards 0,000 to Oncology Research at The Children’s Hospital of Philadelphia
PHILADELPHIA, May 31, 2011 /PRNewswire-USNewswire/ — Cookies for Kids’ Cancer, a nonprofit foundation dedicated to raising funds and awareness for pediatric cancer research, has awarded $ 200,000 in grants to the Cancer Center at The Children’s Hospital of Philadelphia, one of the largest pediatric cancer centers in the United States, and home to the Center for Childhood Cancer Research.
Read more on PR Newswire via Yahoo! News

Technorati Tags: 2017, Adds, Assessment, Cancer, Forecasts, market, Pipeline, Reportlinker, Testicular, Therapeutics